Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict chemo risks for seniors with cancer

NCT ID NCT07151794

Knowledge-focused Sponsor: Çanakkale Onsekiz Mart University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether three easy-to-use health checklists (G8, CARG, and Frailty scales) can predict chemotherapy side effects in people aged 65 and older with solid tumors. Researchers will also check if these scores relate to nutrition blood tests and the need for a drug called G-CSF. The goal is to help doctors personalize treatment and reduce harm in older patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which older cancer patients are at higher risk for chemotherapy side effects, allowing for safer, more personalized treatment plans.
What could go wrong
This is an observational study, not testing a new treatment. The results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study group consists of cancer patients aged 65 and older who are scheduled to receive at least two cycles of chemotherapy. Patients with hematological malignancies or receiving concurrent targeted, hormonal, immunotherapy, or radiotherapy are excluded.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 65 years * Diagnosed with solid tumor malignancy * Planned to undergo at least two cycles of adjuvant, neoadjuvant, or metastatic chemotherapy * Clinically stable condition * Provided written informed consent Exclusion Criteria: * Presence of hematological malignancies * Concurrent hormonal therapy, targeted therapy, immunotherapy, or radiotherapy * Acute infection or advanced organ failure (cardiac, hepatic, renal) * Cognitive or psychiatric impairment preventing test participation * Prior treatment with G-CSF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geriatric oncology are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Frailty neoplasm nutritional disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geriatric oncology Nutrition Nutrition assessment Oncology

Contacts and locations

Locations

  • Çanakkale Onsekiz Mart Univercity

    Çanakkale, 17020, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.